Screening compound: C25H35N5O3 (E525-0241)

Screening compound: C<sub>25</sub>H<sub>35</sub>N<sub>5</sub>O<sub>3</sub> (E525-0241)
Screening compound: C<sub>25</sub>H<sub>35</sub>N<sub>5</sub>O<sub>3</sub> (E525-0241) alternative view

Chemical Structure Depiction of ChemDiv screening compound
C25H35N5O3 (E525-0241)

Available from 1 mg

Formats:

  • Glass Vials (4ml Glass Vials VWR #97047-678)
  • 96-tube racks (Matrix #4247 96-well 1.4ml sealed with capmats, empty cols 1 & 12, 100uL of 10mM)

Shiptime: 1 week worldwide delivery in most cases

Compound Identifiers

ChemDiv Compound ID

E525-0241

Molecular Formula

C25H35N5O3 (C25 H35 N5 O3)

Compound Name

3-methyl-N~3~-(4-methylcyclohexyl)-2-(2-morpholinoethyl)-1-oxo-1,2,3,4-tetrahydropyrazino[1,2-a][1,3]benzimidazole-3-carboxamide

IUPAC name

12-methyl-N-(4-methylcyclohexyl)-11-[2-(morpholin-4-yl)ethyl]-10-oxo-1811-triazatricyclo[7.4.0.0^{27}]trideca-2468-tetraene-12-carboxamide

SMILES

CC(CC1)CCC1NC(C(C)(Cn1c2nc3c1cccc3)N(CCN1CCOCC1)C2=O)=O

InChI

InChI=1S/C25H35N5O3/c1-18-7-9-19(10-8-18)26-24(32)25(2)17-29-21-6-4-3-5-20(21)27-22(29)23(31)30(25)12-11-28-13-15-33-16-14-28/h3-6,18-19H,7-17H2,1-2H3,(H,26,32)/t18?,19?,25-/m0/s1

InChI Key

BLBBWBIYRYWLLG-BRVOVERQSA-N

MDL Number (MFCD)

MFCD27599826

C25H35N5O3 (E525-0241) in Drug Discovery

Included in Screening Libraries

3D-Pharmacophore Based Diversity Library (49813 compounds)

Anti-infective Library (19449 compounds)

300k Representative Compounds Library (Bemis-Murcko Clustering Algorithm) (286253 compounds)

CNS Targets (44014 compounds)

Cyclic Ugi PPI Library (9586 compounds)

DGK Inhibitors Library (10558 compounds)

GPCR Targeted Library (31838 compounds)

PI3K-Targeted Library (17255 compounds)

Protein-Protein Interaction Library (218420 compounds)

Targeted Diversity Library (40567 compounds)

Developmental Pathway (Hh/Wnt) Set (2238 compounds)

Peptidomimetic Library (37031 compounds)

Included in 1.7M Stock Database

Therapeutical areas:
  • Infections
  • Immune system
  • animal
  • Nervous system
  • Cancer
  • Digestive system
  • Hemic and lymphatic
  • Skin
  • Metabolic
  • Immune system
  • Musculoskeletal
  • Respiratory tract
  • Nervous system
  • Congenital
  • Skin
  • Metabolic
  • Endocrine
  • Cancer
  • Digestive system
  • Respiratory tract
  • Otorhinolaryngologic
  • Male
  • Female
  • Hemic and lymphatic
  • Skin
  • Cancer
  • Digestive system
  • Female
  • Hemic and lymphatic
  • Skin
Mechanism of action:
  • PPI modulators
  • Receptor's ligands
  • PPI modulators
  • PPI modulators
Structure:
  • Cyclic compounds
  • Mimetics
Targets:
  • Kinases
  • GPCR
  • Kinases
  • Others

References: we are preparing a list of scientific research reports with C25H35N5O3 (E525-0241) chemical compound. It will be published here after verification.

Frequently Asked Questions

How to purchase chemical compound C25H35N5O3 (E525-0241)?
Check Price and Availability of C25H35N5O3 (E525-0241), then you can add required amount to the Shopping Cart. In the Shopping Cart you can again refine your selection. Once you are sure that it’s exactly what you want you can move forward with the Checkout (to pay online by credit card, or via PayPal), or Request a Quote.
What is the minimum amount of C25H35N5O3 (E525-0241) you sell to drug discovery company or institution?
Available from 1 mg in Glass Vials or 96-tube racks.
Delivery options for C25H35N5O3 (E525-0241)
ChemDiv sends parcels with Express services (UPS, WC).
  • 1–2 days for small orders
  • 2–4 weeks for large selections
Delivery formats for C25H35N5O3 (E525-0241)
  • 0.5–50 mg of dry powder sample in single glass vials, custom vials
  • DMSO solutions frozen 10μl–250μl@10mM (96 and 384 format)

Custom synthesis of C25H35N5O3 (E525-0241) available by request